By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: FDA Releases Draft Social Media Guidance 5 Years After Public Hearing
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > eHealth > Social Media > FDA Releases Draft Social Media Guidance 5 Years After Public Hearing
BusinessSocial Media

FDA Releases Draft Social Media Guidance 5 Years After Public Hearing

David Harlow
David Harlow
Share
0 Min Read
SHARE

FDAFive years after its most recent public hearing on the subject of social media marketing of drugs and medical devices, the FDA released a draft FDAFive years after its most recent public hearing on the subject of social media marketing of drugs and medical devices, the FDA released a draft Guidance for Industry Internet/Social Media Platforms with Character Space Limitations— Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices. Publication was prompted by a statutory deadline in the FDASIA, and there is a 90-day comment period now open.

FDA DRAFT Guidance for Industry Internet/Social Media Platforms with Character Space Limitations

One key issue regarding FDA regulation of short-form internet marketing has long been fair balance — communicating risks as well as benefits.

The FDA draft guidance boils down to three key points:

1. Benefit information should be accurate and non-misleading and reveal material facts within each individual character-space-limited communication (e.g., each individual message or tweet).

2. Benefit information should be accompanied by risk information within each individual character-space-limited communication.

3. If a firm concludes that adequate benefit and risk information, as well as other required information, cannot all be communicated within the same character-space-limited communication, then the firm should reconsider using that platform for the intended promotional message.

More specifically, risk and benefit information should be balanced:

1. Risk information should be presented together with benefit information within each individual character-space-limited communication (e.g., each individual message or tweet).

2. The content of risk information presented within each individual character-space-limited communication should, at a minimum, include the most serious risks associated with the product.

3. A mechanism, such as a hyperlink, should also be provided within each individual character-space-limited communication to allow direct access to a more complete discussion of risk information about the product.

4. The prominence of risk information should be comparable to the benefit information within each individual character-space-limited communication, taking into consideration any formatting capabilities available on the specific Internet/social media platform.

In the end, then, the “one-click rule” bandied about within the industry in the years leading up to the most recent FDA public hearing on the subject has become memorialized in the agency’s draft guidance.

The FDA detailed sample tweets and short-form Google ads, and gave annotated examples of satisfactory character-limited ads, including, for example:

NoFocus (rememberine HCl) for mild to moderate memory loss-May cause seizures in 502 patients with a seizure disorder www.nofocus.com/risk

This tweet includes brand and established names, just a dash to separate benefits from risks, and a link to the safety information page of the product website.

This represents a great leap forward. No doubt there will be much to delve into and consider in order to prepare comments for submission to the agency, and there are issues to be considered in the related draft correction of misinformation guidance released simultaneously by the FDA.

TAGGED:FDAsocial media guidelines
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

Epidemiological Health Benefits
Personal and Epidemiological Health Benefits of Blood Pressure Management
Health
October 13, 2025
Traumatic Brain Injuries
Understanding Traumatic Brain Injuries: What Families Need to Know
Policy & Law
October 10, 2025
Remote Monitoring touchpoints
Remote Monitoring Touchpoints Patients Will Actually Follow
Technology
October 9, 2025
dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025

You Might also Like

Business

Think Like A CEO: Must-Have Skills For Business AND Medicine Today

November 20, 2012
ehr_medical_records
eHealthHospital AdministrationMedical RecordsRadiology

EHRs Play Critical Role in Radiology Decision-Making

January 4, 2015

Strong Deal Flow in Digital Health Defines 1H’14

July 1, 2014
ACA delays
BusinessHealth ReformNewsPolicy & Law

ACA Delays Increase Marketplace Confusion

July 23, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?